• Background: There is inconclusive evidence from randomized controlled trials (RCTs) to support any specific criteria for pharmacologic therapy dose adjustment in diabetes (DM) in pregnancy.
• Data sources: MEDLINE, OVID and Cochrane Library were searched from their inception to November 2016.
• Methods of study selection: Selection criteria included all trials of DM in pregnancy managed by oral hypoglycemic agents or insulin reporting criteria for pharmacologic therapy dose adjustment. RCTs in women with pregestational DM and gestational DM (GDM) were included. For each trial, data regarding glucose values used for pharmacologic therapy dose adjustment were extracted and carefully reviewed.
• Results: Of 51 RCTs on therapy for GDM or pregestational DM, 17 (4,230 women) were included as they reported criteria for pharmacologic therapy dose adjustment. Most of them (88%, 15/17) included women with GDM only. For RCTs including women with GDM, 12/16 (75%) used the two step approach; 3 (19%) used the one step approach; 1 (6%) used either the one or two step approach. Regarding the type of initial therapy, 13 (77%) RCTs used different types and doses of insulin; 9 (53%) used metformin; 4 (24%) used glyburide; 1 (6%) used glybenclamide; and 1 (6%) used placebo. In most RCTs glucose monitoring was assessed four times daily, i.e. fasting (all RCTs) and 2 hours (15 RCTs, 88%) after each of the three main meals -breakfast, lunch, and dinner. For fasting glucose target, all used a value <105 mg/dL; 9 (53%) used 95 mg/dL as target. Of the 15 RCTs using 2 hour-postprandial value as target, 11 (73%) had 120 mg/dL as cutoff. Regarding the criteria for pharmacologic therapy dose adjustment, we found six different criteria. The majority of RCTs (9/17, 53%) used either 1 or 2 values per week higher than the target values, of which two thirds used only 1 value (35% of total), and one third (18% of total) 2 values. Five RCTs (29%) used >50%, 1 (6%) used >30%, and 1 (6%) used >20% of the values higher than the target value; while 1 (6%) used appearance of glycosuria. 
RESULTS
A Fasting value and after each main meal -breakfast, lunch, and dinner -(either 1 or 2 hours). B Fasting and 2 hours after each main meal -breakfast, lunch, and dinner. C Fasting, preprandial before lunch and dinner, 1 and 2 hours after each main meal -breakfast, lunch, and dinner. D Fasting and 1 hour after each main meal -breakfast, lunch, and dinner. E Intervention group: at fasting, 2 hours after each main meal -breakfast, lunch, and dinner. Control group: at fasting, 2 hours after breakfast, 1hour before lunch, 2 hours after lunch, 1 hour before dinner, 2 hours after dinner and at 3am in the morning. F, fasting; 2h, 2 hours postprandial, BW, body weight Metformin: increased by 500-850 mg every 1-2 weeks, maximum 2500 mg daily. Insulin was added, with reduction of the daily dose of metformin to 1000 mg, if needed after 1 week on maximum metformin dose Insulin (regular + NPH): increments of 1 IU/10 mg glucose higher than the desired cut-off; short-acting insulin was added whenever needed When evaluating RCTs which included criteria for pharmacologic GDM therapy dose adjustment, the most common criterion for diagnosis was the two step test, and the most common used therapies insulin and metformin. Regarding glucose monitoring, the most common frequency was four times per day, fasting and 2 hours after each main meal, using as target glucose values 95mg/dL and 120mg/dL, respectively. Importantly, we found six different criteria for pharmacologic GDM therapy dose adjustment, with the majority using very tight criteria of either 1 or 2 values per week higher than the target values, of which two thirds used only 1 value, and one third 2 values.
CONCLUSIONS

